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Misunderstood MTBE
Your recent article panning methyl-tert-
butyl ether use (EHP 102:913) was
extremely misleading and focused on
unpublished, and therefore not critically
reviewed data, which is inconsistent with
standards ofscientific journals. Given the
confusion caused by the article, you
should provide more accurate information
to your readers on why methyl-tert-butyl
ether (MTBE) is in gasoline and how it is
being managed in a manner protective of
public health.
In 1990, Congress passed the Clean
Air Act Amendments, which contained a
requirement to include oxygen in fuel to
reduce carbon monoxide (CO) emissions
from motor vehicles. Once oxygenates
were required by law, the industry began
the process of tooling up for the produc-
tion of oxygenated fuels. Either alcohols
or ethers can be added to provide oxygen
and both have been used previously.
During the 1979 fuel crisis, alcohols had
been added to gasoline to form gasohol.
MTBE was added to gasoline as an octane
enhancer after the lead phase-out. MTBE
had also been used in a three-year pilot
CO reduction program in the Southwest
beginning in the winter of 1989-1990.
There was a considerable body oftoxi-
cological data on MTBE, including neu-
rotoxicity studies, genetic toxicity studies,
and reproduction and developmental
studies. In addition, preliminary results
were available from chronic bioassays in
rats and mice prior to the onset of the
winter fuels program. These results did
not suggest MTBE would be hazardous,
particularly at the low concentrations
likely to be encountered in fuel use. Thus,
required by law to add an oxygenate,
industry legitimately made MTBE its
principal choice. Ethanol, however, is also
widely used, and other compounds such
as ethyl-tert-butyl ether, tert-amyl methyl
ether, and tert-butyl alcohol are being
considered. Oxygenates have been added
to winter fuel in 39 cities since November
1992 for CO reduction and are now in
reformulated gasoline, which has been
required to be sold in approximately 35
geographic areas to reduce ozone since
January 1, 1995.
How has the oxygenate program
fared? From the standpoint ofCO reduc-
tion, it has been successful. EPA esti-
mates that "a reduction of over 2 billion
pounds of carbon monoxide annually is
associated with the winter program."
There have been a few complaints from
users about reactions to the new product,
something not surprising given MTBE's
very distinctive ether odor. In 1989,
there were a few complaints in the
Southwest, but they disappeared in 1990
and 1991. With the initiation ofthe win-
ter fuel program in 1992, there were scat-
tered complaints in New York, Montana,
and more frequent complaints in Alaska
and New Jersey. Industry responded by
collaborating with EPA to conduct sever-
al studies to assess exposure during nor-
mal activities and attempting to duplicate
exposures to assess health effects in
human volunteers in controlled laborato-
ry situations.
The results of these studies were reas-
suring. Exposures during refueling and
commuting were consistently low, averag-
ing 0.3-0.5 ppm during refueling. Acute
symptoms described in the complaints
could not be replicated in clinical cham-
ber studies (1). Finally, in a study com-
paring healthy garage workers exposed to
high and low MTBE concentrations, no
differences in self-reported symptoms
could be demonstrated that were attribut-
able to MTBE exposure (2).
We still hear reference to complaints
in New Jersey, although principally from
representatives of groups, not from indi-
viduals. We find these complaints per-
plexing since New Jersey law minimizes
exposures by requiring stage II vapor
recovery systems throughout the state
and by not allowing self-service fueling
stations. It is also interesting to note that
oxygenated fuels are widely used in vari-
ous parts of the United States, yet the
complaints appear to be focused in New
Jersey.
In summary, the government mandat-
ed the use ofoxygenates in fuels, and the
industry is complying with that mandate.
There is a large body of toxicologic data
about MTBE, which makes up the largest
fraction of oxygenates currently in use.
That data do not suggest untoward health
effects from the very limited exposures
encountered during normal use of gaso-
line. Both government and industry have
managed introduction of MTBE and
responded to legitimate complaints in an
appropriate manner. The article you pub-
lished was incorrect and misleading and
not representative ofthe quality ofarticles
that should appear in your publication.
Robert T. Drew
American Petroleum Institute
Washington, DC
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Clarification
The November 1994 issue of EHP con-
tained a forum article on methyl-tert-
butyl ether that referred to the North
Carolina scientific Advistory Board's
review of the carcinogenicity data for
MTBE. The conclusion ofthe article stat-
ed that "The Board concluded that the
state should consider requesting that the
EPA remove MTBE from gasoline
because of the uncertainties surrounding
it." This statement is incorrect. We did
not make such a recommnedation. The
following summary represents our report
to the North Carolina Department of
Environment, Health and Natural
Resources.
George Lucier, chair
Mary Beth Genter
Y.J. Lao
Woodhall Stopford
Tom Starr
North Carolina Scientific Advisory Board
on Toxic Air Pollutants
Summary ofthe Carcinogenicity
Assessment ofMTBE conducted by
the Secretary's Scientific Advisory
Board on Toxic Air Pollutants
Abstract. The Secretary's Scientific
Advisory Board on Toxic Air Pollutants
(SAB) examined the scientific evidence
pertaining to MTBE carcinogenicity and
came to a consensus agreement that,
according to the National Toxicology
Program (NTP) classification of carcino-
genic activity, there is "some evidence"
for carcinogenicity of MTBE in animals.
The SAB agreed "some evidence" approx-
imately corresponds to the "C" classifica-
tion by the EPA. In an exception to the
SAB policy of not quantifying risk for
group C carcinogens, a range ofexposures
that could be associated with a potential
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risk of 1 in 100,000 (1 x 10-5) was calcu-
lated. This range is 0.04 mg/m3 to 0.64
mg/m3 The annual concentration esti-
mated by the EPA that maximally
exposed people would be subjected to in
areas with a 4-month oxyfuel season
ranges between 0.03 and 0.05 mg/m3.
SAB and EPA estimations indicate that
the range of potential risk of maximally
exposed people in North Carolina may be
between 1 x 10-5 and zero at current
exposure levels.
Data assessment. The merits and defi-
ciencies ofthe scientific information rele-
vant to MTBE carcinogenicity were con-
sidered carefully and are summarized
below.
Two chronic inhalation studies have
been performed, one on F344 rats, the
other on CD-1 mice; exposures were 400,
3,000, and 8,000 ppm MTBE, 6 hours
per day, 5 days per week (1,2). Problems
with the studies include MTBE-induced
toxicity (other than induction of neo-
plasms), decreased survival of high-dose
animals, and substantially shorter than
lifetime exposures. These problems
impart considerable uncertainity to appli-
cation of the resulting data to carcino-
genicity hazard characterization.
An increase in kidney tumor inci-
dence (combined adenomas and carcino-
mas) in male rats exposed to 3,000 ppm
MTBE via inhalation was considered to
contribute to the weight of evidence of
carcinogenicity. There was no significant
increase in tumor formation in male rats
exposed to 8,000 ppm MTBE in the
same study. The dose-response effect
required to attribute the tumors to
MTBE exposure unequivocally may not
have been detected because the 8,000
ppm dose group was sacrificed 15 weeks
before the 3,000 ppm group due to
excess mortality among subjects. Had the
high dose group lived longer, they may
have developed tumors. The SAB consid-
ered the possibility that tumor formation
was due to induction ofa-2.-globulin, a
protein specific to male rats and not rele-
vant to other animals or humans. The
kidney tumors could not be attributed
solely to induction of the a-2. protein
mechanism because an overabundance of
a-2U was not detected in histological sec-
tions of treated rats, though a pattern of
pathology similar to that associated with
a-2U was observed. The SAB considered
the possibility that kidney tumors
observed in this study were secondary to
toxicological damage resulting from
exceedance of the maximum tolerated
dose. Though kidney damage preceded
tumors, a chronic study conducted by the
NTP on a major metabolite of MTBE,
tert-butyl alcohol (TBA), produced evi-
dence of kidney tumors at a dose not
exceeding the maximum tolerated dose
when TBA was administered in drinking
water. The male rat kidney tumors may
not be attributed fully to the toxic effect
of MTBE on the kidney, or to induction
ofa-2u globulin, but may be due to a
TBA-mediated mechanism. There are no
data available to use for a quantitative
comparison ofrodent and human MTBE
metabolism.
Increased interstitial cell adenoma
tumor incidence observed in the testes of
male rats in the inhalation study men-
tioned above was considered to contribute
to the weight ofevidence ofcarcinogenic-
ity. A significant dose response in tumor
incidence was seen from 64% in concur-
rent controls to 94% among the high-
dose rats. The historical incidence of tes-
ticular adenomas in these rats ranges from
86 to 91%, but concurrent controls are
generally considered the most appropriate
controls for comparison. The high spon-
taneous background rate of testicular
tumors in this strain of rat makes inter-
pretation of the significance of the data
difficult, but the clear dose-response
effect compels the SAB to include these
benign tumors in the weight of evidence
ofcarcinogenicity.
Female CD-1 mice exposed to 8,000
ppm MTBE exhibited a significant
increase in liver adenoma tumor inci-
dence, which was considered part of the
weight of evidence for carcinogenicity.
No increase in tumor incidence was
observed at the lower two doses. Body
weight gain in mice exposed to 8,000
ppm was decreased 24% compared to
controls, which may indicate the maxi-
mum tolerated dose was exceeded.
Male mice exposed to 8,000 ppm
MTBE exhibited an increase in liver car-
cinoma incidence, which was considered
part ofthe weight ofevidence for carcino-
genicity. Body weight gain in male mice
exposed to 8,000 ppm was reduced by
15%, and the mortality rate of males was
increased at this dose. These factors indi-
cate the 8,000 ppm exposure may have
exceeded the maximum tolerated dose in
male mice.
A chronic study in which MTBE was
administered to Sprague-Dawley rats by
gavage in an olive oil vehicle reportedly
has been conducted in Italy by Maltoni. A
representative ofMaltoni's laboratory, Dr.
Myton Mehlman, reported "dose-related"
increases in combined lymphoma and
leukemias, hematoreticular tumors, uter-
ine sarcomas, and testicular Leydig cell
tumors in MTBE-treated rats. The experi-
mental design and results of this study
have not been sufficiently reported or
reviewed to allow the information to be
used in a weight-of-the-evidence evalua-
tion ofcarcinogenicity.
The SAB concludes there is "some evi-
dence" for carcinogenicity of MTBE in
animals according to NTP guidelines for
peer-reviewed data characterizing carcino-
genic activity of chemicals. The board
recognizes "some evidence" in the NTP
classification system approximately corre-
sponds to a "C" carcinogen in the EPA
classification system. The board's policy
as recommended in 1986 by the North
Carolina Academy of Sciences is not to
assess carcinogenicity risks for compounds
the EPA has designated group C carcino-
gens. The SAB was asked specifically to
review carcinogenicity of MTBE because
its use as an oxygenate in gasoline could
result in exposure of a large number of
people to MTBE. In an exception to the
policy ofnot quantifying risk for group C
carcinogens, the board estimated a range
ofexposure levels that could be as high as
10-5 risk.
Assuming MTBE is a carcinogen in
humans, the data from animal studies
were used by the SAB to calculate an esti-
mate ofhuman risk due to exposure. The
calculations were based on the kidney
tumor incidence in male rats chronically
exposed to 3,000 ppm ofMTBE. Human
unit risks were calculated using four dif-
ferent equations to estimate a range of
ambient concentrations of MTBE which
would pose an acceptable risk to a person
exposed continuously for 70 years. An
acceptable risk level of 10-5 was used, as
suggested in the North CarolinaAcademy
ofSciences Report and Recommendations
to the Air Toxics Panel (3), for animal
carcinogens (known human carcinogens
are set at 10-6 risk). The range ofconcen-
trations at a risk of 10-5 calculated by the
SAB was 0.04 mg/m3 to 0.64 mg/m3. A
concentration range rather than a single
concentration is submitted by the board
to the Department of Environment,
Health and Natural Resources because
uncertainty inherent in the data makes
one estimation no more realistic than
another. The lower concentration is clear-
ly the most conservative.
The EPA summary ofhealth effects of
MTBE contains exposure estimates for
the general public based on limited sam-
pling conducted at gas stations, at the
property lines of gas stations, and inside
commuting cars (4). These concentrations
are purported to be reasonable worst-case
estimates applicable to working adults
who live near gas stations or major road-
ways. The annual MTBE concentration
estimated by the EPA for maximally
exposed people in areas with a four-
month oxyfuel season ranges between
0.03 and 0.05 mg/mr3.
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Conclusion. The SAB determined
there is some evidence for carcinogenicity
ofMTBE in animals. The SAB estimated
a human risk of cancer due to MTBE
exposure by extrapolating from the ani-
mal data to estimate a risk to humans.
The risk calculations were used to esti-
mate concentrations of MTBE which
would pose minimal risk to humans
exposed continuously for 70 years. The
range of concentrations calculated by the
SAB expected to pose a 10-5 risk was 0.04
mg/m3 to 0.64 mg/m3. The EPA estimat-
ed that an adult commuter who lives next
to a gas station could be exposed to 0.03
to 0.05 mg/m3 of MTBE annually in a
locale which has a four-month oxyfuel
season. The SAB and EPA estimations
indicate that the range ofpotential risk of
maximally exposed people in North
Carolina may be between 1 x 10-5 and
zero at current exposure levels.
REFERENCES
1. Chun et al. Bushy Run Research Center.
Docket no. OPTS 42908, 1992.
2. Burleigh-Flayer et al. Bushy Run Center.
Docket no. OPTS 42908, 1992.
3. NCAS. Report and recommendations to the
Air Toxics Panel. Raleigh, NC:North
Carolina Academy ofSciences, 1986.
4. U.S. EPA. Assessment ofpotential health risks
of gasoline oxygenated with MTBE. EPA
600/R-93/206. Washington, DC: U.S.
Environmental Protection Agency, 1994.
Society Of Environmenta Geoc emistry
anI HeaI h
Announcing the
SECOND INTERNATIONAL CONFERENCE ON ARSENIC EXPOSURE
& HEALTH EFFECTS,
to b'e held June 12-14, 1995. Issues the meeting will acdress include: Dioavailability,
toxicokinetics, close-response relationships, EF'A's arsenic risk assessment., control
strategies, and the health effects of arsenic. The conference will b~e held at the Holida~y
Inn on the Day at the EmLarcadero in L'eautiful San Diego.
For further information contact:
International Conference on Arsenic Exposure
anci Health Effects
Dr. Willard R. Chappell
CaIpus Dox 13i
University of Colorado at Denver
r'ost Office 13ox 17h364
Denver, CO 80217-3564
E'hone: (030) 556-4520
Fax: (303) 556-4292
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